Cargando…
The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up
Background: The wearable cardioverter-defibrillator (WCD) is available for patients at high risk for sudden cardiac death (SCD) when immediate implantable cardioverter-defibrillator (ICD) implantation is not possible or indicated. Patient selection remains challenging especially in primary preventio...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141506/ https://www.ncbi.nlm.nih.gov/pubmed/32214048 http://dx.doi.org/10.3390/jcm9030893 |
_version_ | 1783519207684571136 |
---|---|
author | Rosenkaimer, Stephanie L. El-Battrawy, Ibrahim Dreher, Tobias C. Gerhards, Stefan Röger, Susanne Kuschyk, Jürgen Borggrefe, Martin Akin, Ibrahim |
author_facet | Rosenkaimer, Stephanie L. El-Battrawy, Ibrahim Dreher, Tobias C. Gerhards, Stefan Röger, Susanne Kuschyk, Jürgen Borggrefe, Martin Akin, Ibrahim |
author_sort | Rosenkaimer, Stephanie L. |
collection | PubMed |
description | Background: The wearable cardioverter-defibrillator (WCD) is available for patients at high risk for sudden cardiac death (SCD) when immediate implantable cardioverter-defibrillator (ICD) implantation is not possible or indicated. Patient selection remains challenging especially in primary prevention. Long-term data on these patients is still lacking. Methods: 153 patients were included in this study. They were prescribed the WCD between April 2012 and March 2019 at the University Medical Center, Mannheim, Germany. The mean follow-up period was 36.2 ± 15.6 months. Outcome data, including all-cause mortality, were analyzed by disease etiology and ICD implantation following WCD use. Results: We analyzed 56 patients with ischemic cardiomyopathy, 70 patients with non-ischemic cardiomyopathy, 16 patients with prior need for ICD/CRT-D (device for cardiac resynchronization therapy with defibrillator) explanation, 8 patients with acute myocarditis and 3 patients with congenital diseases. 58% of the patients did not need ICD/CRT-D implantation after WCD use. 4% of all patients suffered from appropriate WCD shocks. 2 of these patients (33%) experienced appropriate ICD shocks after implantation due to ventricular tachyarrhythmias. Long-term follow-up shows a good overall survival. All-cause mortality was 10%. There was no significant difference between patients with or without subsequent ICD implantation (p = 0.48). Patients with ischemic cardiomyopathy numerically showed a higher long-term mortality than patients with non-ischemic cardiomyopathy (14% vs. 6%, p = 0.13) and received significantly more ICD shocks after implantation (10% of ischemic cardiomyopathy (ICM) patients versus 3% of non-ischemic cardiomyopathy (NICM) patients, p = 0.04). All patients with ventricular tachyarrhythmias during WCD use or after ICD implantation survived the follow-up period. Conclusion: Following WCD use, ICD implantation could be avoided in 58% of patients. Long-term follow-up shows good overall survival. The majority of all patients did not suffer from WCD shocks nor did receive ICD shocks after subsequent implantation. Patient selection regarding predictive conditions on long-term risk of ventricular tachyarrhythmias needs further risk stratification. |
format | Online Article Text |
id | pubmed-7141506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71415062020-04-15 The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up Rosenkaimer, Stephanie L. El-Battrawy, Ibrahim Dreher, Tobias C. Gerhards, Stefan Röger, Susanne Kuschyk, Jürgen Borggrefe, Martin Akin, Ibrahim J Clin Med Article Background: The wearable cardioverter-defibrillator (WCD) is available for patients at high risk for sudden cardiac death (SCD) when immediate implantable cardioverter-defibrillator (ICD) implantation is not possible or indicated. Patient selection remains challenging especially in primary prevention. Long-term data on these patients is still lacking. Methods: 153 patients were included in this study. They were prescribed the WCD between April 2012 and March 2019 at the University Medical Center, Mannheim, Germany. The mean follow-up period was 36.2 ± 15.6 months. Outcome data, including all-cause mortality, were analyzed by disease etiology and ICD implantation following WCD use. Results: We analyzed 56 patients with ischemic cardiomyopathy, 70 patients with non-ischemic cardiomyopathy, 16 patients with prior need for ICD/CRT-D (device for cardiac resynchronization therapy with defibrillator) explanation, 8 patients with acute myocarditis and 3 patients with congenital diseases. 58% of the patients did not need ICD/CRT-D implantation after WCD use. 4% of all patients suffered from appropriate WCD shocks. 2 of these patients (33%) experienced appropriate ICD shocks after implantation due to ventricular tachyarrhythmias. Long-term follow-up shows a good overall survival. All-cause mortality was 10%. There was no significant difference between patients with or without subsequent ICD implantation (p = 0.48). Patients with ischemic cardiomyopathy numerically showed a higher long-term mortality than patients with non-ischemic cardiomyopathy (14% vs. 6%, p = 0.13) and received significantly more ICD shocks after implantation (10% of ischemic cardiomyopathy (ICM) patients versus 3% of non-ischemic cardiomyopathy (NICM) patients, p = 0.04). All patients with ventricular tachyarrhythmias during WCD use or after ICD implantation survived the follow-up period. Conclusion: Following WCD use, ICD implantation could be avoided in 58% of patients. Long-term follow-up shows good overall survival. The majority of all patients did not suffer from WCD shocks nor did receive ICD shocks after subsequent implantation. Patient selection regarding predictive conditions on long-term risk of ventricular tachyarrhythmias needs further risk stratification. MDPI 2020-03-24 /pmc/articles/PMC7141506/ /pubmed/32214048 http://dx.doi.org/10.3390/jcm9030893 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Rosenkaimer, Stephanie L. El-Battrawy, Ibrahim Dreher, Tobias C. Gerhards, Stefan Röger, Susanne Kuschyk, Jürgen Borggrefe, Martin Akin, Ibrahim The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up |
title | The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up |
title_full | The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up |
title_fullStr | The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up |
title_full_unstemmed | The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up |
title_short | The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up |
title_sort | wearable cardioverter-defibrillator: experience in 153 patients and a long-term follow-up |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141506/ https://www.ncbi.nlm.nih.gov/pubmed/32214048 http://dx.doi.org/10.3390/jcm9030893 |
work_keys_str_mv | AT rosenkaimerstephaniel thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT elbattrawyibrahim thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT drehertobiasc thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT gerhardsstefan thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT rogersusanne thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT kuschykjurgen thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT borggrefemartin thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT akinibrahim thewearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT rosenkaimerstephaniel wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT elbattrawyibrahim wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT drehertobiasc wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT gerhardsstefan wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT rogersusanne wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT kuschykjurgen wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT borggrefemartin wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup AT akinibrahim wearablecardioverterdefibrillatorexperiencein153patientsandalongtermfollowup |